Document:

Amendment to Collaboration and License Agreement, dated December 4, 2000

 Exhibit 10.3 
  
 Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this Exhibit has been filed separately with the Securities and Exchange Commission. 
  
 EXECUTION COPY 
  
 AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT 
  
 This Amendment to Collaboration and License Agreement (hereinafter the “Amendment”), dated as of December 4, 2000 (the “Effective
Date”), is made by and between GPC Biotech AG (formerly GPC AG-GENOME PHARMACEUTICALS CORPORATION), a German stock corporation having its principal place of business at Fraunhofer Strasse 20, 85152 Martinsried, Munich, Germany
(“GPC”), and MORPHOSYS AG, a German stock corporation with its principal place of business at Lena-Christ-Str. 48, 82152 Martinsried, Munich, Germany (“MORPHOSYS”). MORPHOSYS and GPC are each hereafter referred to individually as
a “Party” and together as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, GPC and MORPHOSYS are
parties to that certain Collaboration and License Agreement having an effective date of April 15, 1999 (the “Collaboration and License Agreement”); and 
  
 WHEREAS, GPC and MORPHOSYS desire to amend the Collaboration and License Agreement, as set forth herein. 
  
 NOW THEREFORE, in consideration of the mutual covenants and promises
contained herein, and intending to be legally bound, GPC and MORPHOSYS mutually agree as follows: 
  
 ARTICLE I. AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT 
  
 1. Defined Terms. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Collaboration and License
Agreement. 
  

 2. Amendment of Collaboration and License Agreement. The Collaboration and License Agreement is
hereby amended as follows: 
  
 (a) The last sentence of Section
3.1(a) of the Collaboration and License Agreement is hereby deleted in its entirety and replaced with the following text: 
  
 “To facilitate the exercise of the rights granted to GPC hereunder, MORPHOSYS hereby agrees to take all reasonable measures to grant, or cause to be
granted to GPC, sublicenses under certain technology and intellectual property rights therein (the “Third Party Rights”). The Third Party Rights are established and defined in the following four agreements (the “Technology
Agreements”): 
  

	 	(i)	License Agreement by and among MORPHOSYS and DYAX CORP. and PROTEIN ENGINEERING CORPORATION, dated October 4, 1996 (the “Dyax Agreement”); 

  

	 	(ii)	License Agreement by and between MORPHOSYS and GENENTECH, INC. dated December April 30, 2000 (the “Genentech Agreement”); 

  

	 	(iii)	Non-Exclusive Derived Product License Agreement between SCA VENTURES INC. and MORPHOSYS dated December 10, 1999 (the “SCA Agreement”); and 

  

	 	(iv)	Collaboration Agreement between BIOSITE DIAGNOSTICS INCORPORATED and MORPHOSYS dated January 1, 2000 (the “Biosite Agreement”). 

  
 GPC hereby acknowledges that it has received summary or redacted versions of
the Technology Agreements and the respective third party patent rights are attached hereto as Exhibit A. Pursuant to the Dyax Agreement, the Genentech Agreement and the SCA Agreement, MORPHOSYS hereby grants to GPC a sublicence of MORPHOSYS’
rights under those Third Party Agreements; provided that: (i) the sublicense under the Genentech Agreement shall become effective only upon the execution and delivery by GPC of the agreement entitled “Morphosys Partner Agreement” which
pertains to the Genentech, Inc. Third Party Rights; (ii) the sublicense under the Dyax Agreement shall become effective only upon the execution and delivery by GPC of the agreement entitled “Third Party Agreement” which pertains to the
Dyax Corp. and Protein Engineering 

  

 2 

 
Corporation Third Party Rights; and (iii) the sublicense under the SCA Agreement shall become effective only upon the execution and delivery by GPC of the
agreement entitled “Third Party Agreement” which pertains to the SCA Ventures, Inc. Third Party Rights (each of the referenced three agreements are attached hereto as Exhibit B). In addition, MORPHOSYS hereby grants to GPC a sublicense of
the Dower Patent Rights (as that term is defined in the Biosite Agreement). For the avoidance of doubt, MORPHOSYS does not grant a sublicense of the Xoma Patent Rights (as such term is defined in the Biosite Agreement) to GPC hereunder; however,
MORPHOSYS agrees to make a written request of Biosite, in accordance with Section 3.1.3 of the Biosite Agreement, that Biosite grant a sublicense to GPC of the Xoma Patent Rights (as such term is defined in the Biosite Agreement). 
  
 MORPHOSYS used reasonable care in preparing the MORPHOSYS intellectual
property (IP) summary dated October 2000 (attached hereto as Exhibit C) in light of such summary’s intended use, and, to the extent such summary contains statements of fact, such statements of fact were, to the best of MORPHOSYS’
knowledge, true as of the date the summary was prepared. In addition, the milestone and royalty payments due under the Technology Agreements and for John Hopkins University patent rights (which are part of MORPHOSYS Background Inventions (TRIM
technology)) are summarized under Exhibit D. 
  
 ARTICLE 2.
MISCELLANEOUS 
  
 1. Fee. As consideration for the
grant rights hereunder, GPC shall pay to MORPHOSYS a total fee of *** US Dollars (US$***), of which *** US Dollars (US$***) will be due upon execution of this Agreement and *** US Dollars (US$***) will be due 15 days after the Effective Date of this
Amendment. The remaining *** US Dollars (US$***) will be due 120 days after the Effective Date of this Amendment. All payments will be made by GPC upon receipt of a corresponding invoice by MORPHOSYS. 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 3 

 2. Confirmation. Except as expressly amended by this Amendment, the Collaboration and License
Agreement shall remain unmodified and in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This
Amendment shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts (excluding its body of law controlling conflicts of law). 
  
 IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Amendment as of the
Effective Date set forth above. 
  

									
	MorphoSys AG	 	 	 	GPC Biotech AG
					
	By:	 	 /s/ S.E. Moroney
	 	 	 	By:	 	 /s/ Dr. Elmar Maier

	 Name:
	 	 S.E. Moroney
	 	 	 	 Name:
	 	 Dr. Elmar Maier

	 Title:
	 	 C.E.O
	 	 	 	 Title:
	 	 Vice President Business Development

	 	 	 	 	 	 	 	 	 
					
	By:	 	 /s/ D. Lemus
	 	 	 	By:	 	 /s/ Sebastian Meier-Ewert

	 Name:
	 	 D. Lemus
	 	 	 	 Name:
	 	 Sebastian Meier-Ewert

	 Title:
	 	 CFO
	 	 	 	 Title:
	 	 Vice President, Head Research

  

 4 

 EXHIBIT A 
  
 THIRD PARTY PATENT RIGHTS 
  

	1)	Dyax Corp. Patent Rights in relation to its phage display technology 

  
 U.S. Patents Nos. 5,223,409, 5,403,484, and 5,571,698, 5,837,500, and EP Patent No. 436,597, together with any continuations, continuations-in-part,
divisionals, reexaminations, renewals, or extensions thereof, and any foreign counterpart thereto. 
  

	2)	Genentech Patent Rights in relation to a special embodiment of the phage display technology: 

  
 U.S. Patents Nos.5,750,373, 5,780,279, 5,821,047 and 5,846,765 together with any continuations, continuations-in-part,
divisional applications, re-examinations, renewals, or extensions thereof, and any foreign counterparts thereto, including EP 564 531. 
  

	3)	SCA Venture Patent Rights in relation to single-chain Fv fragments and display of such fragments on the surface of organisms such as phages. 

  

													
	 Title

	 	 Inventor

	 	 Country

	 	 Date Filed

	 	 Serial No.

	 	 Patent No.

	 	 Date Issued

							
	 Single
	 	Ladner,	 	US	 	09/02/86	 	06/902,971	 	Abandoned	 	 
							
	 Polypeptide
	 	Bird	 	 	 	 	 	 	 	 	 	 
							
	 Chain Molecules
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	US	 	09/02/87	 	07/092,110	 	Abandoned	 	 
							
	 	 	 	 	PCT	 	09/02/87	 	PCT/US87/02208	 	 	 	 
							
	 	 	 	 	EP	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Austria	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Belgium	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	France	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93

  

 5 

													
	 Title

	 	 Inventor

	 	 Country

	 	 Date Filed

	 	 Serial No.

	 	 Patent No.

	 	 Date Issued

							
	 	 	 	 	Germany	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Italy	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Luxem-bourg	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Netherlands	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Sweden	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	Switzerland	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	U. Kingdom	 	09/02/87	 	87906006.9	 	0281604	 	03/31/93
							
	 	 	 	 	CA	 	09/04/87	 	546164	 	 	 	 
							
	 	 	 	 	Japan	 	09/02/88	 	219589	 	 	 	 
							
	 	 	 	 	US	 	01/19/89	 	07/299,617	 	4,946,778	 	08/07/90
							
	 	 	 	 	US	 	04/25/90	 	07/512,910	 	5,260,203	 	11/09/93
							
	 	 	 	 	US	 	04/01/93	 	08/040,440	 	5,455,030	 	10/03/95
							
	 	 	 	 	US	 	06/06/95	 	08/468,988	 	5,518,889	 	05/21/96
							
	 	 	 	 	US	 	06/06/95	 	08/468,992	 	5,534,621	 	07/09/96
							
	 Computer Based
	 	Ladner	 	US	 	09/02/86	 	06/902,970	 	4,704,692	 	11/03/87
							
	 System and
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Method for
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Determining
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Possible
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Chemical
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Structures
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	PCT	 	09/02/87	 	PCT/US87/02211	 	 	 	 
							
	 	 	 	 	EP	 	09/02/87	 	87906007.7	 	Abandoned	 	 
							
	 	 	 	 	US	 	11/02/87	 	07/115,919	 	Abandoned	 	 

  

 6 

													
	 Title

	 	 Inventor

	 	 Country

	 	 Date Filed

	 	 Serial No.

	 	 Patent No.

	 	 Date Issued

							
	 	 	 	 	US	 	06/09/88	 	07/204,940	 	4,881,175	 	Abandoned
							
	 Organism
	 	Ladner,	 	***	 	***	 	***	 	***	 	***
							
	 Carrying a Single
	 	Glick, Bird	 	 	 	 	 	 	 	 	 	 
							
	 Chain Antibody
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Domain at its
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Surface
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	PCT	 	03/02/88	 	PCT/US88/00716	 	 	 	 
							
	 	 	 	 	EP	 	03/02/88	 	88903058.1	 	0349578	 	11/30/94
							
	 	 	 	 	France	 	03/02/88	 	88903058.1	 	0349578	 	11/30/94
							
	 	 	 	 	Germany	 	03/02/88	 	88903058.1	 	0349578	 	11/30/94
							
	 	 	 	 	UK	 	03/02/88	 	88903058.1	 	0349578	 	11/30/94
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 Incremental
	 	Hardman	 	US	 	09/02/87	 	07/092,147	 	4,939,666	 	07/03/90
							
	 Macromolecule
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Construction
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Method
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	CA	 	09/01/88	 	576,386	 	Abandoned	 	 
							
	 	 	 	 	JP	 	9/02/88	 	221223	 	 	 	 
							
	 Linkers for
	 	Whitlow,	 	US	 	11/20/92	 	07/980,529	 	 	 	 
							
	 Linked Fusion
	 	Filpula	 	 	 	 	 	 	 	 	 	 
							
	 Polypeptides
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	US	 	01/15/93	 	08/002,845	 	 	 	 
							
	 	 	 	 	PCT	 	11/17/93	 	PCT/US93/11138	 	Abandoned	 	 
							
	 	 	 	 	US	 	04/07/94	 	08/224,591	 	5,856,456	 	01/05/99
							
	 	 	 	 	US	 	09/10/97	 	08/926,789	 	 	 	 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 7 

													
	 Title

	 	 Inventor

	 	 Country

	 	 Date Filed

	 	 Serial No.

	 	 Patent No.

	 	 Date Issued

							
	 Antigen Binding
	 	Whitlow,	 	US	 	10/13/94	 	08/323,445	 	5,763,733	 	06/09/98
							
	 Fusion Proteins
	 	Filpula,	 	 	 	 	 	 	 	 	 	 
							
	 	 	Shorr	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	US	 	08/16/95	 	08/515,903	 	5,767,260	 	06/16/98
							
	 	 	 	 	PCT	 	10/13/95	 	PCT/US95/12840	 	Abandoned	 	 
							
	 Stabilized
	 	Lee	 	US	 	04/07/95	 	08/417,855	 	5,656,730	 	08/12/97
							
	 Monomeric
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Protein
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 Compositions
	 	 	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	***	 	***	 	***	 	 	 	 
							
	 Production and
	 	Filpula,	 	***	 	***	 	***	 	***	 	 
							
	 Uses of
	 	Wang,	 	 	 	 	 	 	 	 	 	 
							
	 Glycosylated
	 	Shorr,	 	 	 	 	 	 	 	 	 	 
							
	 Single Chain Fv
	 	Whitlow,	 	 	 	 	 	 	 	 	 	 
							
	 Proteins
	 	Lee	 	 	 	 	 	 	 	 	 	 
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 	 	 	 	***	 	***	 	***	 	***	 	 
							
	 	 	 	 	PCT	 	04/30/98	 	PCT/US98/08662	 	 	 	 
							
	 ***
	 	***	 	***	 	***	 	***	 	 	 	 
							
	 ***
	 	***	 	 	 	 	 	 	 	 	 	 
							
	 ***
	 	***	 	 	 	 	 	 	 	 	 	 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 8 

	4)	Biosite Patent Rights in relation to phage display of multimeric binding proteins: 

  
 Dower Patents 
  

											
	 Country

	  	Serial number

	 	Filing date

	 	Patent number

	  	Issue date

	  	Status

	 US
	  	07/517,659	 	05/01/90	 	5,427,908	  	06/27/95	  	Issued
	 US
	  	08/376,326	 	01/20/95	 	5,580,717	  	12/03/96	  	Issued
	 ***
	  	***	 	***	 	 	  	 	  	***
	 PCT
	  	US91/02989	 	05/01/91	 	—  	  	 	  	Published
	 EPO
	  	91908963,1	 	05/01/91	 	0527839	  	12/02/98	  	Granted
	 EPO
	  	98200770,0	 	03/11/98	 	—  	  	 	  	Pending
	 Japan
	  	3-508896	 	05/01/91	 	—  	  	 	  	Pending

  
 XOMA PATENTS

  

			
	 Title:
	  	Modular Assembly of Antibody Genes. Antibodies Prepared Thereby and Use
	 Inventors:
	  	Robinson, Liu, Horwitz, Wall, Better

  

	1)	Based on PCT/US86/02269, which is a continuation-in-part of U.S. Serial No. 06/793.980 filed November 1, 1985 (abandoned) 

  

					
	 Country

	  	 Serial No.

	  	 Patent No.

	 *United States
	  	06/793,980	  	 
	 Australia
	  	65981/86	  	Issued 606,320
	 Canada
	  	521,909	  	Pending
	 Denmark
	  	3385/87	  	Pending
	 Taiwan
	  	75105650	  	Issued 51922
	 *United States
	  	06/086,266	  	 

  

 9 

	2)	Based on PCT/US88/02514, which corresponds to U.S. Serial No. 07/077,528 which is a continuation-in-part of 06/086,266 (abandoned), which is a continuation-in-part of U.S. Serial
No. 06/793,980 (abandoned). 

  

					
	 Country

	  	 Serial No.

	  	 Patent No.

	 Australia
	  	23244/88	  	Issued 632,462
	 Austria
	  	EP88907510.7	  	Granted EP/0371998
	 Belgium
	  	EP 88907510.7	  	Granted EP/0371998
	 Canada
	  	572,398	  	Pending
	 Denmark
	  	192/90	  	Pending
	 Europe
	  	EP 88907510.7	  	Granted EP/0371998
	 Europe
	  	EP 95119798.7	  	Pending (divisional)
	 France
	  	EP 88907510.7	  	Granted EP/0371998
	 Germany
	  	EP 88907510.7	  	Granted EP/0371998
	 Italy
	  	EP 88907510.7	  	Granted EP/0371998
	 Japan
	  	506481/88	  	Pending
	 Luxembourg
	  	EP 88907510.7	  	Granted EP/0371998
	 Netherlands
	  	EP 88907510.7	  	Granted EP/0371998
	 Sweden
	  	EP 88907510.7	  	Granted EP/0371998
	 Switzerland/Liechtenstein
	  	EP 88907510.7	  	Granted EP/0371998
	 United Kingdom
	  	EP 88907510.7	  	Granted EP/0371998
	 Europe
	  	EP 93100041.8	  	Granted EP/0550400

  

	*	Cases Abandoned in favor of a continuing application 

  

					
	 Austria
	  	EP 93100041.8	  	Granted EP/0550400
	 Belgium
	  	EP 93100041.8	  	Granted EP/0550400
	 France
	  	EP 93100041.8	  	Granted EP/0550400
	 Germany
	  	EP 93100041.8	  	Granted EP/0550400
	 Italy
	  	EP 93100041.8	  	Granted EP/0550400
	 Luxembourg
	  	EP 93100041.8	  	Granted EP/0550400
	 Netherlands
	  	EP 93100041.8	  	Granted EP/0550400
	 Sweden
	  	EP 93100041.8	  	Granted EP/0550400
	 Switzerland/Liechtenstein
	  	EP 93100041.8	  	Granted EP/0550400
	 United Kingdom
	  	EP 93100041.8	  	Granted EP/0550400
	 *United States
	  	07/077,528	  	 

  

 10 

	3)	Based on U.S. Serial No. 07/501.092 filed March 29, 1990, which is a continuation-in-part of U.S. Serial No. 07/077, 528 (Modular Assembly of Antibody Genes, Antibodies Prepared
Thereby and Use; Robinson, Liu, Horwitz, Wall, Better) and of U.S. Serial No. 07/142,039 (Novel Plasmid Vector with Pectate Lyase Signal Sequence; Lei, Wilcox). 

  

					
	 Country

	  	 Serial No.

	  	 Patent No.

	 *United States
	  	07/501,092	  	 
	 *United States
	  	07/987,555	  	 
	 *United States
	  	07/870,404	  	 
	 *United States
	  	08/020,671	  	 
	 United States
	  	08/235,225	  	5,618,920
	 United States
	  	08/299,085	  	5,595,898
	 United States
	  	08/357,234	  	5,576,195
	 United States
	  	08/472,696	  	Allowed
	 United States
	  	08/472,691	  	Pending
	 United States
	  	08/467,140	  	5,698,435
	 United States
	  	08/450,731	  	5,693,493
	 United States
	  	08/466,203	  	5,698,417

  

	*	Cases abandoned in favor of a continuing application 

  

			
	 Title:
	  	 Novel Plasmid Vector with Pectate Lyase Signal Sequence

	 Inventors:
	  	 Lei, Wilcox

  
 Based on U.S. Serial No. 07/142,039
filed January 11, 1988 and PCT/US89/00077 
  

					
	 Country

	  	 Serial No.

	  	 Patent No.

	 Australia
	  	29377/89	  	Issued/627443
	 Canada
	  	5887.885	  	I.338,807
	 Europe
	  	EP 89901763.6	  	Granted EP/0396612
	 Austria
	  	EP 89901763.6	  	Granted EP/0396612
	 Belgium
	  	EP 89901763.6	  	Granted EP/0396612
	 France
	  	EP 89901763.6	  	Granted EP/0396612
	 Germany
	  	EP 89901763.6	  	Granted EP/0396612
	 Italy
	  	EP 89901763.6	  	Granted EP/0396612
	 Luxembourg
	  	EP 89901763.6	  	Granted EP/0396612

  

 11 

					
	 Netherlands
	  	EP 89901763.6	  	Granted EP/0396612
	 Sweden
	  	EP 89901763.6	  	Granted EP/0396612
	 Switzerland/Liechtenstein
	  	EP 89901763.6	  	Granted EP/0396612
	 United Kingdom
	  	EP 89901763.6	  	Granted EP/0396612
	 Japan
	  	501661/89	  	Pending
	 *United States
	  	07/142.039	  	 

  

	*	Cases abandoned in favor of a continuing application 

  

 12 

 EXHIBIT B 
  
 Attached hereto are the three Third Party Agreements. 
  
 DYAX AGREEMENT 
  
 Third Party Agreement 
  
 The undersigned hereby acknowledges that Dyax Corp. and Protein Engineering Corporation (collectively, “Licensor”), each having a principal
place of business at 765 Concord Avenue, Cambridge, Massachusetts 02138, have licensed certain patent rights to and under U.S. Patent No. 5,223,409 entitled “Directed Evolution of Novel Binding Proteins”, U.S. Patent No. 5,403,484 entitled
“Viruses Expressing Chimeric Binding Proteins”, and 5,571,698, 5,837,500, and EP Patent No. 436,597 and associated patent rights, to (“Licensee”) under a License Agreement (the “License”) effective as of, a copy of
which has been provided to the undersigned by Licensee; and that the undersigned as a Third Party Transferee expects to receive from Licensee or its Affiliates one or more Licensed Intermediates or services or proprietary information with respect to
one or more Licensed Intermediates (collectively, the “Transferred Technology”). All terms not otherwise defined herein shall have the meanings ascribed to them in the License. 
  
 1. In consideration of the value of the patent rights referenced above in
developing the Transferred Technology, the undersigned agrees (a) to use the Transferred Technology solely within the Field of Use to make, have made, use, sell and have sold Licensed Products (collectively, “Covered Products”); and (b) to
maintain and retain complete and accurate records of sales of Covered Products and any amounts paid or payable to Licensee in relation to such Covered Products, all in accordance with Section 4.4 of the License. 
  
 2. If the undersigned is notified, by Licensor or Licensee or otherwise, that
the License has been terminated in accordance with its terms, such termination shall not affect the rights of the undersigned to make, use and sell Covered Products; provided, however, that the 

  

 13 

 
undersigned hereby agrees that from and after the date of such termination the undersigned shall have the obligation (a) to pay directly to Licensor all
amounts due pursuant to the Payment Schedule elected by Licensee under Section 4.1 of the License (as determined, in the event of any conflict, by the records of Licensor), including royalties on Net Sales, with respect to all Covered Products
(which shall be deemed for purposes of this paragraph to be “Licensed Products” as defined in the License), and (b) deliver directly to Licensor all reports otherwise due to Licensee pursuant to paragraph 1 above. All such payments and
reports shall be subject to the terms and conditions therefor set forth in the License, which are incorporated herein. To the extent that the foregoing constitutes a grant of rights to the undersigned under Patent Rights with respect to the
Transferred Technology, such rights shall be contingent and, in the event of a failure to make any such payments or any other material breach by the undersigned, terminate upon thirty (30) days notice unless the breach is cured prior to expiration
of such period. Licensor shall not be deemed to have assumed, and will not be liable for, any representations, warranties or obligations of Licensee to the undersigned. 
  
 3. This Agreement is executed and delivered as an instrument under seal expressly for the benefit of each of Licensor and
Licensee and their respective Affiliates and permitted successors and shall be subject to the terms of Article 8 of the License, which are incorporated herein.  
  

					
	 {Company Name}
	 	 	 	Address:

  

 14 

 SCA-VENTURES AGREEMENT 
  
 THIRD PARTY AGREEMENT 
  
 The undersigned hereby acknowledges that SCA VENTURES Inc., a corporation of the State of Delaware (SCA VENTURES) having its principal place of business
at 20 Kingsbridge Road, Piscataway, New Jersey 08854-3969, USA has licensed certain SCA VENTURES PATENT RIGHTS to MORPHOSYS AG (LICENSEE) under a NON-EXCLUSIVE DERIVED PRODUCT LICENSE AGREEMENT effective as of
                    , a redacted copy of which has been provided to the undersigned by LICENSEE; and that the undersigned, as a THIRD PARTY
TRANSFEREE, expects to receive, or receive services or proprietary information with respect to, an INTERMEDIATE, INTERMEDIATE PRODUCT(S) or DERIVED PRODUCT(S) or a sublicense of all or a portion of the rights granted to LICENSEE under the attached
NON-EXCLUSIVE DERIVED PRODUCT LICENSE AGREEMENT (collectively, the TRANSFERRED TECHNOLOGY) from the LICENSEE or its AFFILIATES. All terms not otherwise defined herein shall have the same meanings set forth in the attached NON-EXCLUSIVE DERIVED
PRODUCT LICENSE AGREEMENT. 
  
 1. In consideration of the value of
the SCA VENTURES PATENT RIGHTS in developing the TRANSFERRED TECHNOLOGY, the undersigned agrees (a) to use the TRANSFERRED TECHNOLOGY solely to develop, make, use, sell, offer for sale and import DERIVED PRODUCTS, or (b) to use the TRANSFERRED
TECHNOLOGY only in accordance with its agreement with LICENSEE, if more restrictive. The undersigned further agrees that in no event will it sell, transfer or license an INTERMEDIATE or an INTERMEDIATE PRODUCT without first obtaining the written
approval of SCA VENTURES. 
  
 If the undersigned is notified, by
SCA VENTURES or LICENSEE or otherwise, that the NON-EXCLUSIVE DERIVED PRODUCT LICENSE AGREEMENT has been terminated in accordance with its terms, such termination shall not affect the rights of the undersigned to develop, make, use, sell, offer for
sale and import DERIVED PRODUCTS; provided, however, 

  

 15 

 
that the undersigned hereby agrees that from and after the date of such termination the undersigned shall be bound by the terms and conditions of the
NON-EXCLUSIVE DERIVED PRODUCT LICENSE AGREEMENT. To the extent that the foregoing constitutes a grant of rights to the undersigned under SCA VENTURES PATENT RIGHTS with respect to the TRANSFERRED TECHNOLOGY, such rights shall be contingent and, in
the event of any material breach by the undersigned, shall terminate upon thirty (30) days written notice from SCA VENTURES unless the breach is cured prior to expiration of such period. SCA VENTURES and its AFFILIATES shall not be deemed to have
assumed, and will not be liable for, any representations, warranties or obligations of LICENSEE to the undersigned. 
  
 This THIRD PARTY AGREEMENT is executed and delivered as an instrument under seal expressly for the benefit of each of SCA VENTURES and LICENSEE and their
respective AFFILIATES and permitted successors and assigns. 
  

			
	THIRD PARTY TRANSFEREE:	 	 

			
	Address:	 	 

			
	By:	 	 

			
	Title:	 	 

			
		
	LICENSEE:	 	 

			
	By:	 	 

			
	Title:	 	 

  

 16 

 GENENTECH AGREEMENT 
  
 Morphosys Partner Agreement 
  
 The undersigned hereby acknowledges that Genentech, Inc., having a principal place of business at 1 DNA Way, South San Francisco, California 94080-4990, has granted
certain limited license under U.S. Patent Nos. 5,750,373; 5,780,279; 5,821,047; 5,846,765; EP 564 531 and patents related thereto (“Patent License”), to Morphosys under a License Agreement (the “License Agreement”) effective as
of April 30, 2000, a redacted copy of which has been provided to the undersigned by Morphosys; and that the undersigned as a Morphosys Partner expects to receive from Morphosys one or more Licensed Products, services or proprietary Information with
respect to Morphosys HuCal Technology or Morphosys TRIM Technology (collectively, the “Transferred Technology”). All terms not otherwise defined herein shall have the same meanings set forth in the License Agreement. 
  
 1. In consideration of the value of the Patent License in developing the Transferred
Technology, the undersigned agrees (a) to use the Transferred Technology solely within the Field to research and develop, make, have made, use, sell and have sold Licensed Products (collectively, “Covered Products”); and (b) to maintain
and retain complete and accurate records of sales of Covered Products and any amounts paid or payable to Morphosys in relation to such Covered Products. 
  
 2. If the undersigned is notified, by Genentech or Morphosys or otherwise, that the License Agreement has been terminated in accordance with its terms, such termination
shall not affect the rights of the undersigned to research and develop, make, have made, use, sell and have sold Covered Products; provided, however, that the undersigned hereby agrees that from and after the date of such termination, the
undersigned shall have the obligation (a) to pay directly to Genentech all amounts due pursuant to the License Agreement, with respect to all Covered Products (which shall be deemed for purposes of this paragraph to be “Licensed Products”
as defined in the License Agreement), and (b) deliver directly to Genentech all payments and reports otherwise due to Morphosys pursuant to paragraph 1 above. All such payments and 

  

 17 

 
reports shall be subject to the terms and conditions therefor set forth in the License Agreement, which are incorporated herein. To the extent that the
foregoing constitutes a grant of rights to the undersigned under the Patent License with respect to the Transferred Technology, such rights shall be contingent and, in the event of a failure to make any required payments to Genentech or any other
material breach of this Agreement by the undersigned, such rights under the Patent License shall terminate upon thirty (30) days’ notice (and the undersigned shall have no other rights whatsoever under the License Agreement), unless the breach
is cured prior to expiration of such period. 
  
 3. This Agreement is executed and
delivered as an instrument under seal expressly for the benefit of each of Genentech and Morphosys and their respective Affiliates and permitted successors. 
  

									
	 {Company Name}
	 	 	 	 Address:

					
	By:	 	 	 	 	 	 	 	 
					
	 Title:
	 	 	 	 	 	 	 	 

  

 18 

 EXHIBIT C 
  
 EXHIBIT REMOVED FROM CONTRACT UPON EXECUTION OF AMENDMENT NO. 2 
 TO AGREEMENT 
  

 19 

 EXHIBIT D 
  
 EXHIBIT REMOVED FROM CONTRACT UPON EXECUTION OF AMENDMENT NO. 2 
 TO AGREEMENT 
  

 20Amendment to Collaboration and License Agreement, dated February 23, 2004

 Exhibit 10.4 
  
 Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. 
 A complete version of this Exhibit has been filed separately with the Securities and Exchange Commission. 
  
 EXECUTION COPY 
  
 CONFIDENTIAL 
  
 SECOND AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT 
  
 This Second Amendment to the Collaboration and License Agreement (hereinafter
the “Second Amendment”), dated as of February 23, 2004 (the “Effective Date”), is made by and between GPC Biotech AG (formerly GPC AG-GENOME PHARMACEUTICALS CORPORATION), a German stock corporation having its principal
place of business at Fraunhofer Strasse 20, 82152 Planegg/Martinsried, Germany (“GPC”), and MORPHOSYS AG, a German stock corporation with its principal place of business at Lena-Christ-Str. 48, 82152 Planegg/Martinsried, Germany
(“MORPHOSYS”). MORPHOSYS and GPC are each hereafter referred to individually as a “Party” and together as the “Parties.” 
  
 WHEREAS, GPC and MORPHOSYS are parties to that certain Collaboration and License Agreement having an effective date of April 15, 1999, first amended on
December 4, 2000 (the “First Amendment”), (collectively, the “Agreement”); and 
  
 WHEREAS, GPC and MORPHOSYS desire to amend the Agreement, as set forth herein. 
  
 NOW THEREFORE, in consideration of the mutual covenants and promises contained herein, and intending to be legally bound
thereby, GPC and MORPHOSYS mutually agree as follows: 
  

	 	1.	All Capitalized terms used herein and that are defined in the Agreement herein shall, unless otherwise herein provided, have the meanings ascribed to them in the Agreement.

  

	 	2.	All references herein to section numbers, unless otherwise specifically stated, are references to sections of the Agreement. 

  

	 	3.	Section 1.33 of the Agreement (definition of “Third Party Payment”) is hereby deleted in its entirety. A new Section 1.33 is hereby added to the Agreement, which shall
read as follows: 

  
 “1.33
‘Third Party Payments’ shall mean collectively GPC Third Party Payments and MORPHOSYS Third Party Payments.” 
  

	 	4.	The following provisions are hereby incorporated into the Agreement as new Sections 1.34-1.42, which shall read as follows: 

  

	 	“1.34	‘CAT Licensed Patent Rights’ shall mean the rights and interests in and to issued patents and pending patent applications from CAMBRIDGE ANTIBODY TECHNOLOGY, which
are listed and described in SCHEDULE 2 of the MORPHOSYS-CAT License Agreement. 

  

	 	1.35	 ‘GPC Third Party Patent Rights’ shall mean the rights and interests conveyed in any agreement between a third party and (i) GPC at any time or (ii)
MORPHOSYS after the Effective Date of the Second Amendment (provided that GPC consents to assume future obligations of such MORPHOSYS-third party agreement or to reimburse MORPHOSYS for such payments, such consent to not be unreasonably withheld),
which agreement (in either case (i) or (ii)) either Party 

  

 1 

	 	 
deems reasonably necessary for the general operation or use of the MORPHOSYS Technologies in order to permit the Parties to perform their obligations under
this Agreement and/or to make, have made, use, offer for sale, sell and/or import Licensed Products. As of the Effective Date of the Second Amendment, MORPHOSYS is not in negotiation and has not scheduled to enter negotiation for any agreement with
a Third Party to access intellectual property it deems necessary for the general operation or use of the MORPHOSYS Technologies in order to permit the Parties to perform their obligations under this Agreement and/or to make, have made, use, offer
for sale, sell and/or import Licensed Products. 

  

	 	1.36	‘GPC Third Party Payments’ shall mean license fees, sublicense fees, milestone payments and royalty payments owed under GPC Third Party Patent Rights, to the extent
any of such fees become due as a result of the general operation or use of the MORPHOSYS Technologies in order to permit the Parties to perform their obligations under this Agreement and/or to make, have made, use, offer for sale, sell and/or import
Licensed Products (for example, fees or payments related to a license for commercial production or a license for a target would not qualify as GPC Third Party Payments). 

  

	 	1.37	‘MORPHOSYS-CAT License Agreement’ shall mean the license agreement entered into by and between MORPHOSYS and CAMBRIDGE ANTIBODY TECHNOLOGY, a true and redacted copy
of which has been previously submitted by MORPHOSYS to GPC, who shall have reviewed such redacted copy of the agreement prior to the Effective Date of the Second Amendment. 

  

	 	1.38	‘MORPHOSYS Third Party Patent Rights’ shall mean the rights and interests in and to issued patents and pending patent applications from GENENTECH, DYAX, and BIOSITE
and SCA VENTURES INC. The MORPHOSYS Third Party Patent Rights are listed and described in Appendix D hereof, and are subject to the limitations and obligations of the agreements between MORPHOSYS and the respective third parties, which have been
affirmed through separate instruments by GPC (to the extent necessary and as shown in Appendix B) in order to become effective. 

  

	 	1.39	‘MORPHOSYS Third Party Payments’ shall mean license fees, sublicense fees, milestone payments and royalty payments owed under MORPHOSYS Third Party Patent Rights,
CAT Licensed Patent Rights, XOMA Covenant Rights and the patent rights licensed by MORPHOSYS from The Johns Hopkins University and described in Exhibit E hereof, to the extent any of such fees become due as a result of the general operation or use
of the MORPHOSYS Technologies in order to permit the Parties to perform their obligations under this Agreement and/or to make, have made, use, offer for sale, sell and/or import Licensed Products. 

  

	 	1.40	‘Third Party Patent Rights’ shall mean collectively the CAT Licensed Patent Rights, the GPC Third Party Patent Rights’ and the MORPHOSYS Third Party Patent
Rights. 

  

 2 

	 	1.41	‘XOMA Covenant’ shall mean the covenant-not-to-sue under the XOMA Covenant Rights and is subject to the limitations and obligations of the agreement between
MORPHOSYS and XOMA IRELAND LIMITED, dated February 1, 2002, a true and redacted copy of which has been previously submitted by MORPHOSYS to GPC, who shall have reviewed such redacted copy of the agreement prior to the Effective Date of the Second
Amendment. 

  

	 	1.42	‘XOMA Covenant Rights’ shall mean the rights and interests in and to issued patents and pending patent applications from XOMA IRELAND LIMITED that are described in
Schedule 1.17 of the XOMA Covenant.” 

  

	 	5.	Section 3.1 of the Agreement is hereby deleted in its entirety. A new Section 3.1 is hereby added to the Agreement, which shall read as follows: 

  

	 	“3.1	License Grant. 

  

	 	(a)	For each GPC Target listed on Appendix A, MORPHOSYS hereby grants to GPC an exclusive license in the Territory to make, have made, use, have used, sell, have sold, offer for
sale, import and have imported Licensed Products directed to such GPC Target for use in the Field under MORPHOSYS Background Inventions, MORPHOSYS Third Party Patent Rights (subject to the limitations according to the agreements between MORPHOSYS
and the respective third party) and under MORPHOSYS’ rights in all Patent Rights, Collaboration Inventions, Collaboration Material, and Collaboration Data pertaining to such GPC Target and Licensed Products or the uses thereof. Such license
shall be perpetual unless terminated in accordance with the terms of this Agreement. 

  

	 	(b)	Upon written request of GPC, MORPHOSYS shall, to the extent permitted by contractual arrangements with third parties, grant to GPC a non-exclusive license in the Territory to make
and use any specified Licensed Product directed against a GPC Target in a clinical setting for patient screening to support the development by GPC of human or animal therapeutic or prophylactic products which are not Licensed Products. Such license
shall be personal to GPC and non-assignable and may only be sublicensed to third parties performing patient screening on behalf of GPC, and shall be granted under MORPHOSYS Background Inventions, MORPHOSYS Third Party Patent Rights (subject to the
limitations according to the agreements between MORPHOSYS and the respective third party) and under MORPHOSYS’ rights in all Patent Rights, Collaboration Inventions, Collaboration Material, and Collaboration Data pertaining to such GPC Target
and Licensed Products or the uses thereof. In the event of any such grant, the Parties shall execute an amendment to this Agreement to effect such grant and the sole payments therefor shall be the payments to be made to MORPHOSYS according to the
terms of Sections 4.4(f) through (h) hereof. 

  

	 	(c)	 For each GPC Target listed on Appendix A, and so long as GPC possesses a license under Section 3.1(a) for such Target, MORPHOSYS hereby grants to GPC,
subject to the limitations of the MORPHOSYS-CAT License Agreement, a non-exclusive license in the Territory to make, have made, use, 

  

 3 

	 	 
have used, sell, have sold, offer for sale, import and have imported Licensed Products directed to such GPC Target for use in the Field under CAT Licensed
Patent Rights. 

  

	 	6.	Section 3.4 of the Agreement is hereby deleted in its entirety. A new Section 3.4 is hereby added to the Agreement, which shall read as follows: 

  

	 	3.4	Research License and Covenant to GPC. 

  
 (a) Research License to GPC. 
  
 (1) MORPHOSYS hereby grants to GPC a non-exclusive, royalty-free research license under MORPHOSYS Background Inventions, MORPHOSYS Third
Party Patent Rights (subject to the limitations according to the agreements between MORPHOSYS and the respective third party) and MORPHOSYS’ interests in any Collaboration Material and Collaboration Inventions, solely during the Collaboration
Term and as further described below, to the extent necessary to allow GPC to perform its obligations under the Collaboration Program. 
  
 (2) MORPHOSYS hereby grants to GPC, subject to the limitations of the MORPHOSYS-CAT License Agreement, and so long as GPC has a research
license under Section 3.4(a)(1) and to the extent necessary, a non-exclusive research license under CAT Licensed Patent Rights to allow GPC to perform its obligations under the Collaboration Program. 
  
 (b) Grant of the Benefit of the XOMA Covenant. MORPHOSYS hereby
grants to GPC the benefits of the XOMA Covenant (subject to the limitations to the agreement between MORPHOSYS and XOMA), so long as GPC has a research license under Section 3.4(a) and to the extent necessary, to allow GPC to perform its obligations
under the Collaboration Program. 
  
 (c) No right granted under
this Section shall include the right to develop or commercialize any products other than as set forth in Section 3.1 hereof. 
  

	 	7.	The following provision is hereby incorporated into the Agreement as a new Section 3.9: 

  

	 	“3.9	No Sublicense or Further Conveyance. The licenses and covenants granted under Section 3.4 shall be personal to GPC and non-sublicensable or further conveyable without the
prior written consent of MORPHOSYS and shall not include the right to utilize any MORPHOSYS Technologies or to perform antibody development, screening, engineering or optimization with respect to any Target which is not a GPC Target.”

  

	 	8.	The following provision is hereby incorporated into the Agreement as a new Section 3.10: 

  

	 	“3.10	Release. As consideration for GPC’s reimbursement obligations under Section 4.6(a) hereof with respect to CAT, MorphoSys hereby conveys to GPC, as a “Defined
Party” under the MORPHOSYS-CAT License Agreement, the benefits of the release of any past, present and future claims of alleged patent infringement from CAT, as such release appears in APPENDIX B-1 to the Settlement Agreement (“CAT
Release”). 

  

 4 

	 	9.	Section 4.6 of the Agreement (relating to Third Party Payments) is hereby deleted in its entirety. A new Section 4.6 is hereby added to the Agreement, which shall read as follows:

  

	 	“4.6	Third Party Payments. 

  
 (a) GPC shall be responsible for making any MORPHOSYS Third Party Payments on behalf of MORPHOSYS that do not relate to milestones, as referenced in
Exhibit D. In order to facilitate such payment by GPC, MORPHOSYS shall inform GPC in writing if any MORPHOSYS Third Party Payment has been triggered by Net Sales, together with detailed information regarding (i) the name and address of the third
party payee, (ii) amount due and payment information for the bank transfer, (iii) due date for such payment, and (iv) the contractual basis for such payment to the Third Parties or John Hopkins University, CAT or XOMA (or their respective assignees)
after the Effective Date of the Second Amendment. If GPC does not fulfill its obligation to make such MORPHOSYS Third Party Payments, then MORPHOSYS shall make such MORPHOSYS Third Party Payments, and GPC shall be obligated to promptly reimburse
MORPHOSYS for such Third Party Payments made by MORPHOSYS. GPC will provide to MORPHOSYS a proof of the payments by GPC to the individual third parties referenced under this Section 4.6(a) as evidenced by reasonably detailed documentation. If
MORPHOSYS has paid then MORPHOSYS will provide to GPC proof of the payments by MORPHOSYS to the individual third parties referenced under this Section 4.6(a) as evidenced by reasonably detailed documentation. 
  
 (b) MORPHOSYS shall be responsible for any MORPHOSYS Third Party Payments
that relate to milestones, as estimated below in this Section 4.6(b). MORPHOSYS will invoice GPC for the respective payments after GPC has achieved the respective milestone, at which time GPC shall reimburse MORPHOSYS within thirty (30) days of
receipt of an invoice for such milestone payments as they were actually made by MORPHOSYS to the Third Parties or John Hopkins University, CAT or XOMA (or their respective assignees) after the Effective Date of the Second Amendment. MORPHOSYS will
provide to GPC a proof of the payments, as evidenced by reasonably detailed documentation: 
  

	 	•	IND milestone payments of € *** 

  

	 	•	phase III commencement milestone payments of € *** 

  

	 	•	NDA filing/approval milestone payments of € *** 

  
 (c) GPC shall be responsible for any GPC Third Party Payments. Should GPC or a Sublicensee enter into a separate agreement with a third party to whom
MORPHOSYS is responsible for MORPHOSYS Third Party Payments, GPC or a Sublicensee may elect to take over responsibility therefor to such third party, and GPC shall discontinue making such Third Party Payments on behalf of MORPHOSYS, provided that
MorphoSys has received a written confirmation from such third party, along with an appropriate release from those future 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 5 

 payment obligations to such third party directly attributable to GPC and such Sublicensee. 
  
 (d) For Licensed Products which have not been sublicensed by GPC, GPC may
reduce the corresponding royalty and milestone payments otherwise due and payable to MORPHOSYS pursuant to Sections 4.4 and 4.5 by *** (***%)] of any relevant Third Party Payments actually paid, but in no event shall any such payments to MORPHOSYS
hereunder be reduced by more than *** (***%). In the event any such Third Party Payment is due for a milestone or royalty which does not correspond to a milestone or royalty payment due to MORPHOSYS hereunder, GPC shall be entitled to carry forward
any credit permitted above to the subsequent milestone or royalty payments for such Licensed Product which become due to MORPHOSYS hereunder. For Licensed Products which have been sublicensed by GPC, the provisions of Section 4.7 shall govern
credits of relevant Third Party Payments from the date of execution of such sublicense and, in such event, this Section 4.6(d) shall not apply. 
  

	 	10.	Section 4.7(c) of the Agreement is hereby deleted in its entirety. A new Section 4.7(c) is hereby added to the Agreement, which shall read as follows: 

  
 (c) Notwithstanding the foregoing, in no event shall MORPHOSYS receive less
than ***%] of the Net Sales of any Sublicensee of such Licensed Product, unless the Parties otherwise mutually agree; provided, however, that the Parties hereby agree that the share of Net Sales to be retained by GPC, after payment of
all Third Party Payments due thereon, shall not be less than the share of Net Sales otherwise due and payable to MORPHOSYS under Section 4.6 hereof. For example, under the formula in Section 4.7(b), if B=***%, C=***%, and if Z=***%, then A would
equal ***% of Net Sales (i.e., ***% of GPC’s ***% net royalty). However, the first clause of this Section 4.7(c) would increase “A” from ***% to ***% of Net Sales. However, the immediately following “provided,
however” clause of this Section 4.7(c) would decrease “A” from ***% to ***% of Net Sales, such that the share of Net Sales to be retained by GPC, after payment of all Third Party Payments due thereon, would equal
“A”, i.e., ***% of Net Sales. 
  

	 	11.	The following provision is hereby incorporated into the Agreement as a new Section 4.14, which shall read as follows: 

  
 Third Party Payment Audits. MORPHOSYS shall keep for three (3)
years from the date of each MORPHOSYS Third Party Payment complete and accurate records of the contractual basis therefor and/or of the execution of such payments by MORPHOSYS (whatever is applicable). GPC shall have the right for a period of three
(3) years after any payment of MORPHOSYS Third Party Payments to appoint an independent certified public accountant reasonably acceptable to MORPHOSYS to inspect the relevant records of MORPHOSYS to verify the contractual basis for such MORPHOSYS
Third Party Payment and/or that MORPHOSYS has made such MORPHOSYS Third Party Payments (whatever is applicable). MORPHOSYS shall make its records available for inspection by such independent certified public accountant during regular business hours
at such place or places where such records are customarily kept, upon reasonable notice from GPC, solely to verify the accuracy of the MORPHOSYS Third Party Payments. Such inspection right shall not be exercised more than once in any calendar year.
GPC agrees to hold in strict 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 6 

 confidence and to cause its accountants to hold in strict confidence all information concerning MORPHOSYS
Third Party Payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for GPC to reveal such information in order to enforce its rights under this Agreement or if disclosure is
required by law, regulation or judicial order. The results of each inspection, if any, shall be binding on both Parties. GPC shall pay for such inspections, except that in the event there is any downward adjustment in aggregate MORPHOSYS Third Party
Payments reimbursable or paid by GPC for any year shown by such inspection of more than five percent (5%), MORPHOSYS shall pay for such inspection. 
  

	 	12.	The following provision is hereby incorporated into the Agreement at the end of Section 9.1: 

  
 Furthermore, to the best knowledge of MORPHOSYS the redacted copies of the agreements between MORPHOSYS and the relevant
third parties (CAT, XOMA, Biosite, SCA Ventures, Dyax, The Johns Hopkins University, Genentech) provided to GPC accurately reflect all of GPC’s obligations, rights and limitations thereunder. 
  

	 	13.	The exhibit entered under the First Amendment as Exhibit A (relating to the “MORPHOSYS Third Party Patent Rights”) is hereby renamed as Appendix D.

  

	 	14.	The exhibit entered under the First Amendment as Exhibit B (relating to third party agreements signed by GPC) is hereby renamed as Appendix B; and original Appendix
B (as defined before the First Amendment) is hereby deleted in its entirety. 

  

	 	15.	Exhibit C of the Agreement (backgrounder on intellectual property and which was entered under the First Amendment) is hereby deleted in its entirety.

  

	 	16.	Exhibit D of the Agreement (relating to third party payments and which was entered under the First Amendment) is hereby deleted in its entirety. A new Exhibit D is
hereby added to the Agreement and is attached after the signature page hereof. 

  

	 	17.	A new exhibit (relating to the The Johns Hopkins University Patent Rights) is hereby added to the Agreement as Exhibit E and is attached after the signature page hereof.

  

	 	18.	No modification to the Agreement or this Second Amendment, including a modification of this clause, shall be effective unless in writing with specific reference to the Agreement and
signed by the Parties. 

  

	 	19.	Except as expressly amended hereby, the Agreement shall continue in full force and effect, and this Second Amendment is incorporated and made a part of the Agreement. In the event
of any conflict or inconsistency between the Agreement and this Second Amendment, the latter shall prevail. 

  
 IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Amendment as of the Effective Date set forth
above. 
  

 7 

									
	MorphoSys AG	 	 	 	GPC Biotech AG
					
	By:	 	 /s/ S.E. Moroney
	 	 	 	By:	 	 /s/ Dr. Elmar Maier

	 Name:
	 	 S.E. Moroney
	 	 	 	 Name:
	 	 Dr. Elmar Maier

	 Title:
	 	 C.E.O
	 	 	 	 Title:
	 	 SVP Business Development

	 Date:
	 	 23.2.04
	 	 	 	 Date:
	 	 23.2.2004

  

									
	 	 	 	 	 
					
	By:	 	 /s/ Stephen S. Yoder
	 	 	 	By:	 	 /s/ Mirko Scherer

	 Name:
	 	 Stephen S. Yoder, Esq.
	 	 	 	 Name:
	 	 Mirko Scherer

	 Title:
	 	 US Counsel
	 	 	 	 Title:
	 	 SVP Finance

	 Date:
	 	 23.02.04
	 	 	 	 Date:
	 	 23.2.2004

  

 8 

 EXHIBIT D (page 1 of 2) 
  

MORPHOSYS Third Party Payments to be paid by GPC: 
  
 In-License Royalties and Royalty Terms 
  

					
	 AGREEMENT

	  	 Royalty

	  	 EXCERPTED LANGUAGE RE: ROYALTY TERM

			
	 ***
	  	***	  	Section 1.31: “Payment Term” shall mean with respect to each Product in each country (a) if, at the time of the First Commercial Sale of such Product in such country, the
development, manufacture, use, offer for sale, sale or import of such Product in such country would be covered by a Valid Claim, the term for which such Valid Claim remains in effect, or (b) otherwise, ten (10) years from the date of the First
Commercial Sale of such Product in such country
			
	 ***
	  	***	  	Section 3.1: Until the expiry of twelve years from the Commencement Date *** MorphoSys shall pay to *** royalties of ***% of Net Sales of each Product. Following that period MorphoSys shall
pay *** ***% of Net Sales of each Product subject to the fact that royalties shall be payable in any country in respect of any Product until the last to expire of any of the Valid Claims of the Licensed Patent Rights in that country or 10 years from
the First Commercial Sale of that Product in that country whichever is the later.
			
	 ***
	  	***	  	 4.2.2. Royalty Payments and Reports. Commencing with the First Commercial Sale of a Licensed Product in any country, within thirty (30) days after
the conclusion of each Royalty Period, Licensee shall deliver to Licensor a report.... Concurrent with these reports, Licensee shall remit to Licensor any payment due for the applicable Royalty Period
 1.11. “Royalty Period” shall mean the calendar quarter, or partial calendar quarter, commencing with the First Commercial Sale of any Licensed Product in each
country, and each calendar quarter thereafter
 1.8.”Licensed Product” shall mean any product intended for sale to an End User as a human
therapeutic that is (i) discovered, made or developed, whether by Licensee, its Affiliates or any Third Party Transferee, using a Licensed Intermediate or a method covered in whole or in part by Patent Rights or (ii) otherwise covered by Patent
Rights.

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 9 

 EXHIBIT D (page 2 of 2) 
  

					
	 AGREEMENT

	  	 Royalty

	  	 EXCERPTED LANGUAGE RE: ROYALTY TERM

			
	 ***
	  	***	  	 7.1 Royalties on Net Sales. At the end of each Royalty Period during the term of this Agreement (a) Morphosys shall pay *** a royalty on aggregate
Net Sales of Finished Products by Morphosys and all Morphosys Partners during the Royalty Period
 1.23 “Royalty Period” shall mean the calendar
quarter or partial quarter commencing with the First Commercial Sale of any Licensed Product, in each country, and each calendar quarter thereafter. The end of a Royalty Period shall be the last day of the applicable calendar quarter, that is,
either March 31, June 30, September 30, or December 31, as the case may be.
 11.1 This Agreement shall commence on the Effective Date and shall continue in
full force and effect, unless earlier terminated pursuant to Articles 11.2 or 11.3, until the expiration on a country-by-country basis of the last to expire Valid Claim contained within the *** Licensed Patent Rights
(“Term”).

			
	 ***
	  	***	  	                             4.5 Any royalties paid to Company by a third party who generates income
from sale or use of a PROTEIN or OTHER PRODUCT developed by Company under a contract with such third party, would be split as follows:
                                        
                 Company                      
                           JHU
     Category
2                                        
***                                        
                 ***
 Category
2:             Company uses technology according to the PATENT RIGHTS to generate DNA and expresses the DNA and screens the resulting library for one or more proteins having improved
functions, which are then provided to the third party.

			
	 ***
	  	***	  	***
			
	 ***
	  	***	  	***

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 10 

 EXHIBIT E 
  

Patent Rights exclusively licensed from The Johns Hopkins University 
  
 based on WO 93/21203: 
 EPO:                  0 638 089 B1 
 USA:                 5,869,644 
 Canada:            2,133,554 
 Japan:               518533/93 
  

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]